Genovax was selected among many applicants, and will be among only 12 SME which will have the opportunity to present to a selected group of international private investors its running projects and future plans. Genovax will illustrate not only the status of its present portfolio of projects - GX101 and GX301 - but also preliminary findings on two new projects - GX201 for immunotherapy and GX401 for atherosclerosis - which are looking for opportunities of collaborations and financial support.

March 2009